Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.27 +0.7%	$5.36	$1.67 ▼ $7.29	$515.92M	0.94	2.41 million shs	1.67 million shs
DNLI Denali Therapeutics	$14.50 +9.6%	$14.29	$10.57 ▼ $33.33	$2.13B	1.36	1.40 million shs	985,298 shs
IDYA IDEAYA Biosciences	$24.28 +2.9%	$22.55	$13.45 ▼ $40.74	$2.13B	0.09	1.15 million shs	263,925 shs
TARS Tarsus Pharmaceuticals	$52.37 +2.0%	$41.82	$24.95 ▼ $57.28	$2.21B	0.79	658,608 shs	218,707 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-6.77%	+0.19%	-1.32%	+72.61%	+188.95%
DNLI Denali Therapeutics	-4.98%	-7.49%	-8.95%	-5.30%	-41.30%
IDYA IDEAYA Biosciences	+3.28%	-2.20%	+4.94%	+37.95%	-37.23%
TARS Tarsus Pharmaceuticals	+2.58%	+24.81%	+31.09%	+19.72%	+95.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.2737 of 5 stars	3.6	1.0	0.0	2.8	1.7	0.6
DNLI Denali Therapeutics	4.2094 of 5 stars	3.6	1.0	4.7	3.4	3.3	0.0
IDYA IDEAYA Biosciences	4.1288 of 5 stars	4.4	1.0	4.4	2.4	1.7	0.0
TARS Tarsus Pharmaceuticals	2.4352 of 5 stars	3.5	2.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$20.20	283.67% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	133.50% Upside
IDYA IDEAYA Biosciences	2.77	Moderate Buy	$48.09	98.04% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	27.30% Upside

Current Analyst Ratings Breakdown

Latest ATYR, DNLI, IDYA, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$66.00 ➝ $72.00
7/22/2025	IDYA IDEAYA Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/10/2025	IDYA IDEAYA Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$25.00
7/9/2025	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$57.00 ➝ $30.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,243.12	N/A	N/A	$0.76 per share	6.93
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$8.53 per share	N/A
IDYA IDEAYA Biosciences	$7M	304.02	N/A	N/A	$10.95 per share	2.22
TARS Tarsus Pharmaceuticals	$182.95M	12.08	N/A	N/A	$7.88 per share	6.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	N/A	-93.69%	-68.83%	N/A
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-39.15%	-35.06%	N/A
IDYA IDEAYA Biosciences	-$274.48M	-$3.79	N/A	N/A	N/A	N/A	-31.42%	-29.45%	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	N/A

Latest ATYR, DNLI, IDYA, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	-$0.88	-$0.03	-$0.88	$3.48 million	$6.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
DNLI Denali Therapeutics	N/A	9.56	9.56
IDYA IDEAYA Biosciences	N/A	12.39	12.39
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
DNLI Denali Therapeutics	92.92%
IDYA IDEAYA Biosciences	98.29%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
DNLI Denali Therapeutics	12.50%
IDYA IDEAYA Biosciences	2.50%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
IDYA IDEAYA Biosciences	80	87.64 million	85.45 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable

ATYR, DNLI, IDYA, and TARS Headlines

Recent News About These Companies

Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87

August 12 at 8:12 PM | msn.com

Blair William & Co. IL Sells 15,814 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 12 at 3:45 AM | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for TARS

August 12 at 2:15 AM | americanbankingnews.com

Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

August 11 at 2:04 AM | marketbeat.com

Brokers Offer Predictions for TARS Q3 Earnings

August 11 at 2:04 AM | marketbeat.com

HC Wainwright Has Optimistic View of TARS FY2027 Earnings

August 10 at 3:41 AM | americanbankingnews.com

Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report

August 9, 2025 | finance.yahoo.com

FY2027 Earnings Forecast for TARS Issued By HC Wainwright

August 9, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Average PT from Brokerages

August 9, 2025 | americanbankingnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 13.4% - What's Next?

August 8, 2025 | marketbeat.com

Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result

August 7, 2025 | finance.yahoo.com

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

August 7, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

August 6, 2025 | globenewswire.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Brokerages

August 6, 2025 | marketbeat.com

Federated Hermes Inc. Lowers Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Has $4.05 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 4, 2025 | marketbeat.com

Tarsus Pharmaceuticals (TARS) Projected to Post Earnings on Wednesday

August 1, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 35,393 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, DNLI, IDYA, and TARS Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.26 +0.04 (+0.67%)

As of 12:46 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Denali Therapeutics NASDAQ:DNLI

$14.50 +1.28 (+9.64%)

As of 12:47 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

IDEAYA Biosciences NASDAQ:IDYA

$24.28 +0.69 (+2.94%)

As of 12:47 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Tarsus Pharmaceuticals NASDAQ:TARS

$52.37 +1.01 (+1.96%)

As of 12:47 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time